




PHARMACEUTICAL 2017

ImmunoGen Inc.
Rank 234 of 292

immu·gen





PHARMACEUTICAL 2017

ImmunoGen Inc.
Rank 234 of 292



The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of ImmunoGen Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -84%, being 87% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	254,780
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	61,439
Liabilities, Non-Current	4,192
Other Assets	9,601
Other Compr. Net Income	-19,826
Other Expenses	0
Other Liabilities	303,758
Other Net Income	0
Other Revenues	60,002
Property and Equipment	22,704
Research and Development	148,077
Selling, General and Administrative Expense	36,916

Output Variable	Value in 1000 USD
Assets	287,085
Liabilities	369,389
Expenses	184,993
Revenues	60,002
Stockholders Equity	-82,304
Net Income	-124,991
Comprehensive Net Income	-134,904
Economic Capital Ratio	-84%